This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Interventions
The treatments under examination were infliximab and adalimumab. The background comparator was usual care, which referred to various conventional non anti-TFN-alpha treatments that included corticosteroids and other immunosuppressants. Infliximab induction therapy comprised infusions of 5mg/kg at weeks zero, two and six. Infliximab maintenance therapy comprised infusions of 5mg/kg every eight weeks. Adalimumab induction therapy comprised a 160mg subcutaneous injection at week zero and an 80mg subcutaneous injection at week two. Adalimumab maintenance therapy comprised 40mg subcutaneous injections every two weeks.
Location/setting
Canada/secondary care.
Methods

Analytical approach:
The analysis was based on a Markov model with a time horizon of five years. The perspective was that of a publicly funded health care system.
Effectiveness data:
Clinical sources of inputs were derived from a systematic review of the literature, the methods and results of which had been presented extensively in a published health technology assessment. Efficacy (remission and response rates) of the two biologic treatments was a key input of the model taken from published clinical trials (none were head-to-head). Each trial provided a specific model input. Placebo arms of the trials were used to estimate the efficacy of usual care arms. Some adjustments were required to pool evidence for the usual care strategy because of differences in the placebo arms of the trials. Other inputs were taken from additional clinical trials and review studies.
Monetary benefit and utility valuations:
Utility valuations were taken from a previous study that used the standard gamble methodology in a sample of Crohn's disease patients. Quality-adjusted life-years (QALYs) were used as the summary benefit measure and were discounted at an annual rate of 5%.
Measure of benefit:
Cost data:
The economic analysis included the costs of initial anti-TFN-alpha treatment, maintenance anti-TFN-alpha treatment, non anti-TFN-alpha outpatient medications and surgery. Drug costs were derived from the manufacturer (infliximab) or official reimbursement rates in three Canadian provinces (adalimumab). A pharmacy mark-up was applied. Costs of chest X-ray, tuberculosis skin test and hepatitis B blood test (performed before the first anti-TFN-alpha treatment) were derived from a hospital participating in the Ontario Case Costing Initiative (OCCI). Quantities of other drugs used in Crohn's disease patients were based on expert opinion and valued using the Ontario Drug Benefit Formulary. The OCCI database was used to estimate in-patient costs. Surgical costs were estimated using official reimbursement rates. A 5% annual discount rate was applied. Costs were reported in Canadian dollars ($). The price year was not reported explicitly.
Analysis of uncertainty:
One-way sensitivity analyses were carried out to investigate the impact of model assumptions, especially those related to patient weight. Alternative sources were used for some inputs. The overall issue of uncertainty was assessed using a probabilistic sensitivity analysis based on 1,000 Monte Carlo simulations and conventional distributions for model inputs. Cost-effectiveness acceptability curves were generated.
Results
Projected The sensitivity analysis showed that both adalimumab and infliximab cost-effectiveness ratios remained higher than $100,000 in all circumstances expect for a reduction of 50% in adalimumab drug cost. The probabilistic sensitivity analysis showed that adalimumab had the greatest probability of being cost-effective at a willingness to pay of $208,000 or more.
